Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.

Li M, Spakowicz D, Burkart J, Patel S, Husain M, He K, Bertino EM, Shields PG, Carbone DP, Verschraegen CF, Presley CJ, Otterson GA, Kendra K, Owen DH.

J Cancer Res Clin Oncol. 2019 Oct;145(10):2541-2546. doi: 10.1007/s00432-019-02982-4. Epub 2019 Jul 31.

2.

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.

Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y.

J Clin Oncol. 2019 Oct 20;37(30):2738-2745. doi: 10.1200/JCO.19.00320. Epub 2019 Jun 4.

3.

Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics.

Kunkler AL, Binkley EM, Mantopoulos D, Hendershot AJ, Ohr MP, Kendra KL, Davidorf FH, Cebulla CM.

Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1771-1781. doi: 10.1007/s00417-019-04337-8. Epub 2019 May 16.

PMID:
31098752
4.

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma.

Suarez-Kelly LP, Levine KM, Olencki TE, Del Campo SEM, Streacker EA, Brooks TR, Karpa VI, Markowitz J, Bingman AK, Geyer SM, Kendra KL, Carson WE.

Cancer Immunol Immunother. 2019 Apr;68(4):619-629. doi: 10.1007/s00262-019-02308-w. Epub 2019 Feb 6. No abstract available.

5.

Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.

Boussemart L, Nelson A, Wong M, Ross JS, Sosman J, Mehnert J, Daniels G, Kendra K, Ali SM, Miller VA, Schrock AB.

Oncologist. 2019 May;24(5):657-663. doi: 10.1634/theoncologist.2018-0271. Epub 2019 Jan 25.

6.

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB.

Cancer. 2019 Jan 1;125(1):18-44. doi: 10.1002/cncr.31719. Epub 2018 Oct 3. Review. Erratum in: Cancer. 2019 Aug 1;125(15):2706.

PMID:
30281145
7.

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.

Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, Kendra K, Campbell A, Gautam S, Abood D, Landi I, Hsu V, Duggan M, Wesolowski R, Old M, Howard JH, Yu L, Stasik N, Olencki T, Muthusamy N, Tridandapani S, Byrd JC, Caligiuri M, Carson WE.

Clin Cancer Res. 2018 Apr 15;24(8):1891-1904. doi: 10.1158/1078-0432.CCR-17-0691. Epub 2018 Jan 23.

8.

Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases.

Williams NL, Wuthrick EJ, Kim H, Palmer JD, Garg S, Eldredge-Hindy H, Daskalakis C, Feeney KJ, Mastrangelo MJ, Kim LJ, Sato T, Kendra KL, Olencki T, Liebner DA, Farrell CJ, Evans JJ, Judy KD, Andrews DW, Dicker AP, Werner-Wasik M, Shi W.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):22-30. doi: 10.1016/j.ijrobp.2017.05.028. Epub 2017 May 26.

PMID:
28816150
9.

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.

Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK.

Melanoma Manag. 2017 Mar;4(1):13-37. doi: 10.2217/mmt-2016-0022. Epub 2017 Mar 1. Review.

10.

Surveillance strategies in the follow-up of melanoma patients: too much or not enough?

Kurtz J, Beasley GM, Agnese D, Kendra K, Olencki TE, Terando A, Howard JH.

J Surg Res. 2017 Jun 15;214:32-37. doi: 10.1016/j.jss.2017.02.070. Epub 2017 Mar 6.

PMID:
28624057
11.

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.

Farren MR, Hennessey RC, Shakya R, Elnaggar O, Young G, Kendra K, Landesman Y, Elloul S, Crochiere M, Klebanov B, Kashyap T, Burd CE, Lesinski GB.

Mol Cancer Ther. 2017 Mar;16(3):417-427. doi: 10.1158/1535-7163.MCT-16-0498. Epub 2017 Feb 1.

12.

A randomized trial of an acceptance-based behavioral intervention for weight loss in people with high internal disinhibition.

Lillis J, Niemeier HM, Thomas JG, Unick J, Ross KM, Leahey TM, Kendra KE, Dorfman L, Wing RR.

Obesity (Silver Spring). 2016 Dec;24(12):2509-2514. doi: 10.1002/oby.21680. Epub 2016 Nov 2.

13.

MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches.

Markowitz J, Abrams Z, Jacob NK, Zhang X, Hassani JN, Latchana N, Wei L, Regan KE, Brooks TR, Uppati SR, Levine KM, Bekaii-Saab T, Kendra KL, Lesinski GB, Howard JH, Olencki T, Payne PR, Carson WE 3rd.

Onco Targets Ther. 2016 Sep 29;9:5931-5941. eCollection 2016.

14.

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.

Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K, Landi I, Zhong Y, Dubovsky J, Howard JH, Yu L, Harrington B, Old M, Reiff S, Mace T, Tridandapani S, Muthusamy N, Caligiuri MA, Byrd JC, Carson WE 3rd.

Cancer Res. 2016 Apr 15;76(8):2125-36. doi: 10.1158/0008-5472.CAN-15-1490. Epub 2016 Feb 15.

15.

Sulfur Biogeochemistry of an Oil Sands Composite Tailings Deposit.

Warren LA, Kendra KE, Brady AL, Slater GF.

Front Microbiol. 2016 Feb 3;6:1533. doi: 10.3389/fmicb.2015.01533. eCollection 2015.

16.

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A.

Ann Oncol. 2015 Nov;26(11):2267-74. doi: 10.1093/annonc/mdv324. Epub 2015 Sep 26.

17.

Weight loss intervention for individuals with high internal disinhibition: design of the Acceptance Based Behavioral Intervention (ABBI) randomized controlled trial.

Lillis J, Niemeier HM, Ross KM, Thomas JG, Leahey T, Unick J, Kendra KE, Wing RR.

BMC Psychol. 2015 May 28;3(1):17. doi: 10.1186/s40359-015-0075-2. eCollection 2015.

18.

Microbial Diversity in Engineered Haloalkaline Environments Shaped by Shared Geochemical Drivers Observed in Natural Analogues.

Santini TC, Warren LA, Kendra KE.

Appl Environ Microbiol. 2015 Aug;81(15):5026-36. doi: 10.1128/AEM.01238-15. Epub 2015 May 15.

19.

Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma.

Mantopoulos D, Kendra KL, Letson AD, Cebulla CM.

JAMA Ophthalmol. 2015 Aug;133(8):965-7. doi: 10.1001/jamaophthalmol.2015.1128. No abstract available.

20.

Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.

Blachly JS, Lozanski G, Lucas DM, Grever MR, Kendra K, Andritsos LA.

J Natl Compr Canc Netw. 2015 Jan;13(1):9-13; quiz 13.

PMID:
25583765
21.

Focal takotsubo cardiomyopathy with high-dose interleukin-2 therapy for malignant melanoma.

Damodaran S, Mrozek E, Liebner D, Kendra K.

J Natl Compr Canc Netw. 2014 Dec;12(12):1666-70; quiz 1670.

PMID:
25505207
22.

A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.

Kendra KL, Plummer R, Salgia R, O'Brien ME, Paul EM, Suttle AB, Compton N, Xu CF, Ottesen LH, Villalona-Calero MA.

Mol Cancer Ther. 2015 Feb;14(2):461-9. doi: 10.1158/1535-7163.MCT-14-0431. Epub 2014 Dec 10.

23.

Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.

Suttle AB, Grossmann KF, Ouellet D, Richards-Peterson LE, Aktan G, Gordon MS, LoRusso PM, Infante JR, Sharma S, Kendra K, Patel M, Pant S, Arkenau HT, Middleton MR, Blackman SC, Botbyl J, Carson SW.

J Clin Pharmacol. 2015 Apr;55(4):392-400. doi: 10.1002/jcph.437. Epub 2014 Dec 30.

PMID:
25449654
24.
25.

Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.

Yang J, Bill MA, Young GS, La Perle K, Landesman Y, Shacham S, Kauffman M, Senapedis W, Kashyap T, Saint-Martin JR, Kendra K, Lesinski GB.

PLoS One. 2014 Jul 24;9(7):e102983. doi: 10.1371/journal.pone.0102983. eCollection 2014.

26.

A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.

Monk P, Lam E, Mortazavi A, Kendra K, Lesinski GB, Mace TA, Geyer S, Carson WE 3rd, Tahiri S, Bhinder A, Clinton SK, Olencki T.

J Immunother. 2014 Apr;37(3):180-6. doi: 10.1097/CJI.0000000000000023.

27.

Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib.

Liebner DA, Walston SA, Cavaliere R, Powers CJ, Sauvageau E, Lehman NL, Wayne Slone H, Xu-Welliver M, Xia F, Kendra KL.

Melanoma Res. 2014 Apr;24(2):172-6. doi: 10.1097/CMR.0000000000000044.

28.

A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.

Markowitz J, Luedke EA, Grignol VP, Hade EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV, Lesinski GB, Olencki T, Kendra KL, Carson WE 3rd.

J Immunother. 2014 Jan;37(1):55-62. doi: 10.1097/CJI.0000000000000009.

29.

Case of sorafenib-induced thyroid storm.

Haraldsdottir S, Li Q, Villalona-Calero MA, Olencki TE, Kendra K, Ing SW.

J Clin Oncol. 2013 Jun 1;31(16):e262-4. doi: 10.1200/JCO.2012.46.7142. Epub 2013 Apr 22. No abstract available.

PMID:
23610115
30.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A.

J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7.

31.

Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue.

He L, Grecula JC, Ling Y, Enzerra MD, Ammirati M, Kendra K, Cavaliere R, Mayr N, McGregor J, Olencki T, Mrozek E, Matharbootham M, Oluigbo C, Phelps MA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Sep 15;905:141-4. doi: 10.1016/j.jchromb.2012.08.013. Epub 2012 Aug 16.

32.

Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.

Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K.

Mol Ther. 2012 Oct;20(10):1998-2003. doi: 10.1038/mt.2012.146. Epub 2012 Aug 7.

33.

A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.

Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, Wei L, Walker MJ, Chen HX, Kendra K, Carson WE 3rd.

J Immunother. 2011 Jul-Aug;34(6):509-15. doi: 10.1097/CJI.0b013e31821dcefd.

34.

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P.

N Engl J Med. 2011 Jun 2;364(22):2119-27. doi: 10.1056/NEJMoa1012863.

35.

Fulminant myocarditis owing to high-dose interleukin-2 therapy for metastatic melanoma.

Thavendiranathan P, Verhaert D, Kendra KL, Raman SV.

Br J Radiol. 2011 May;84(1001):e99-e102. doi: 10.1259/bjr/13448473.

36.

Stereotactic radiosurgery alone for patients with 1-4 radioresistant brain metastases.

Lo SS, Clarke JW, Grecula JC, McGregor JM, Mayr NA, Cavaliere R, Kendra KL, Gupta N, Wang JZ, Sarkar A, Olencki TE.

Med Oncol. 2011 Dec;28 Suppl 1:S439-44. doi: 10.1007/s12032-010-9670-5. Epub 2010 Sep 3.

PMID:
20814764
37.

A pilot study of bevacizumab and interferon-α2b in ocular melanoma.

Guenterberg KD, Grignol VP, Relekar KV, Varker KA, Chen HX, Kendra KL, Olencki TE, Carson WE 3rd.

Am J Clin Oncol. 2011 Feb;34(1):87-91. doi: 10.1097/COC.0b013e3181d2ed67.

38.

Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis.

Clarke JW, Register S, McGregor JM, Grecula JC, Mayr NA, Wang JZ, Li K, Gupta N, Kendra KL, Olencki TE, Cavaliere R, Sarkar A, Lo SS.

Am J Clin Oncol. 2010 Feb;33(1):70-4. doi: 10.1097/COC.0b013e31819ccc8c.

PMID:
19652578
39.

Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha.

Zimmerer JM, Lesinski GB, Ruppert AS, Radmacher MD, Noble C, Kendra K, Walker MJ, Carson WE 3rd.

Clin Cancer Res. 2008 Sep 15;14(18):5900-6. doi: 10.1158/1078-0432.CCR-08-0846.

40.

Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.

Puhalla S, Mrozek E, Young D, Ottman S, McVey A, Kendra K, Merriman NJ, Knapp M, Patel T, Thompson ME, Maher JF, Moore TD, Shapiro CL.

J Clin Oncol. 2008 Apr 1;26(10):1691-7. doi: 10.1200/JCO.2007.14.3941. Epub 2008 Mar 3.

PMID:
18316792
41.

IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2.

Zimmerer JM, Lehman AM, Ruppert AS, Noble CW, Olencki T, Walker MJ, Kendra K, Carson WE 3rd.

Clin Cancer Res. 2008 Mar 1;14(5):1438-45. doi: 10.1158/1078-0432.CCR-07-4178.

42.

Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.

Kondadasula SV, Varker KA, Lesinski GB, Benson DM Jr, Lehman A, Olencki T, Monk JP, Kendra K, Carson WE 3rd.

Cancer Immunol Immunother. 2008 Aug;57(8):1137-49. doi: 10.1007/s00262-007-0444-7. Epub 2008 Jan 10.

PMID:
18193422
43.

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, Wu H, Lesinski GB, Kendra K, Chen HX, Walker MJ, Carson WE 3rd.

Ann Surg Oncol. 2007 Aug;14(8):2367-76. Epub 2007 May 30.

PMID:
17534686
44.

Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.

Varker KA, Kondadasula SV, Go MR, Lesinski GB, Ghosh-Berkebile R, Lehman A, Monk JP, Olencki T, Kendra K, Carson WE 3rd.

Clin Cancer Res. 2006 Oct 1;12(19):5850-8.

45.

Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.

Mrozek E, Ramaswamy B, Young D, Rhoades CA, Kendra K, Allen J, Moore T, Hauger M, Watson H, Merriman N, Nadella P, Villalona-Calero M, Shapiro CL.

Clin Breast Cancer. 2006 Jun;7(2):141-5.

PMID:
16800973
46.

Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.

Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL.

Clin Cancer Res. 2006 May 15;12(10):3124-9.

47.

Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.

Choi BS, Sondel PM, Hank JA, Schalch H, Gan J, King DM, Kendra K, Mahvi D, Lee LY, Kim K, Albertini MR.

Cancer Immunol Immunother. 2006 Jul;55(7):761-74. Epub 2005 Sep 27.

PMID:
16187086
48.

Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.

Ramaswamy B, Povoski SP, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendra K, Somasundaram S, Orlowski RZ, Shapiro CL.

Breast Cancer Res Treat. 2005 Sep;93(1):67-74.

PMID:
16184461
49.

Attitudes toward HIV Health Care Providers scale: development and validation.

Bodenlos JS, Grothe KB, Kendra K, Whitehead D, Copeland AL, Brantley PJ.

AIDS Patient Care STDS. 2004 Dec;18(12):714-20.

PMID:
15659882
50.

Use of the Beck Depression Inventory-II with African American primary care patients.

Dutton GR, Grothe KB, Jones GN, Whitehead D, Kendra K, Brantley PJ.

Gen Hosp Psychiatry. 2004 Nov-Dec;26(6):437-42.

PMID:
15567209

Supplemental Content

Loading ...
Support Center